International Stem Cell Corporation Reports 9% Increase in Product Sales for Q1 2026

International Stem Cell Corporation (ISCO) reported its financial results for the first quarter of 2026, revealing a product sales increase of 9% to $2.315 million, up from $2.129 million in the same period last year. The growth was primarily driven by higher sales in the biomedical market segment, which saw a $140,000 increase in cell and other product sales, alongside a $35,000 rise in media product sales. The company's profit margin improved to 59% from 53%, attributed to a favorable sales mix and fewer inventory write-offs in its skin care product line.

Operating expenses for the quarter totaled $2.505 million, a 7% increase from $2.344 million in the prior year. This rise was largely due to a 26% increase in general and administrative expenses, which reached $1.122 million, primarily driven by higher legal and consulting fees. Research and development expenses decreased by 17% to $156,000, reflecting a strategic decision to reduce consulting costs. The net loss for the quarter narrowed to $220,000 from $256,000 in the previous year, maintaining a consistent net loss per share of $0.03.

In terms of operational metrics, ISCO's cash position decreased slightly to $933,000 as of March 31, 2026, down from $993,000 at the end of 2025. The company reported a total of 8,004,389 shares outstanding, with no significant changes in customer concentration, as one customer accounted for approximately 57% of total product sales. The company continues to face challenges in generating revenue from its therapeutic product candidates, which have yet to yield any sales.

Strategically, ISCO is focused on advancing its research and development efforts, particularly in the therapeutic market for conditions such as Parkinson's disease, traumatic brain injury, and stroke. The company is also exploring various financing options to support its operations, as it has historically incurred net losses and does not generate sufficient cash flow to sustain operations without additional funding. The management has indicated that the ability to continue operations is contingent upon securing further financing or extending existing financial arrangements.

Looking ahead, ISCO's management remains cautious, noting substantial doubt about the company's ability to continue as a going concern without additional capital. The company is actively evaluating financing sources, including equity and debt financing, to support its ongoing research and development programs and operational needs. The financial statements reflect this uncertainty, as they do not include adjustments that may arise from the potential inability to continue operations.